Facioscapulohumeral muscular dystrophy

7 trials 2 recruiting MedDRA PT
7 Registered trials
2 Recruiting
4 Unique sponsors
4 Unique IMPs
7 Commercial trials
Drug classes (ATC)
ATC code not specified 5
N Neurology/Psychiatry (ATC N) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase III: 2 Phase II: 3 Phase I (First in Human): 2

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

2 trials
  • Avidity Biosciences Inc. Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TFR1 CONJUGATED TO DOUBLE STRANDED SIRNA OLIGONUCLEOTIDE AGAINST DUX4 MRNA VIA A NON-CLEAVABLE LINKER
    2025-521012-18-00 6 countries 2026 n=80 Orphan
    Recruiting
  • Fulcrum Therapeutics Inc. Commercial
    LOSMAPIMOD
    2024-512737-33-00 6 countries 2022 n=144 Orphan
    Ended

Phase II

3 trials
  • F. Hoffmann-La Roche AG Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN LATENT MYOSTATIN
    2022-503117-36-00 2 countries 2022 n=27
    Ended
  • Fulcrum Therapeutics Inc. Commercial
    LOSMAPIMOD
    2024-512732-30-00 2 countries 2019 n=11 Orphan
    Ended
  • Fulcrum Therapeutics Inc. Commercial
    LOSMAPIMOD
    2024-512736-29-00 1 country 2019 n=14 Orphan
    Ended

Phase I (First in Human)

2 trials
  • Avidity Biosciences Inc. Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TFR1 CONJUGATED TO DOUBLE STRANDED SIRNA OLIGONUCLEOTIDE AGAINST DUX4 MRNA VIA A NON-CLEAVABLE LINKER
    2022-502096-32-00 2 countries n=12 Orphan
    Ended
  • Sarepta Therapeutics Inc. Commercial
    ADS-010
    2023-509748-89-00 4 countries 2025 n=44
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Fulcrum Therapeutics Inc. Commercial 3 Phase II, Phase III 0
Avidity Biosciences Inc. Commercial 2 Phase III, Phase I (First in Human) 1
F. Hoffmann-La Roche AG Commercial 1 Phase II 0
Sarepta Therapeutics Inc. Commercial 1 Phase I (First in Human) 1
New trials by year
2019
2
2022
2
2025
1
2026
1
← All indication landscapes